Skip to main content

Biotech M&A Could Finally Perk Up in 2022

Broadly speaking, mergers and acquisitions in the healthcare sector were steady in 2021, but for many investors, there weren’t enough aimed at smaller biotechnology companies. As is often the case, market observers are forecasting an uptick in biotechnology consolidation activity next year....
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.